Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|February 25, 2012
Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemiaJonathan M Flanagan, Shirley Steward, Thad A Howard, et al.
American Journal of Hematology|September 16, 2017
A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapyJeremie H Estepp, Matthew P Smeltzer, Guolian Kang, et al.
Blood|February 21, 2013
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemiaJonathan M Flanagan, Vivien Sheehan, Heidi Linder, et al.
The Lancet. Haematology|May 3, 2024
Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trialBanu Aygun, Adam Lane, Luke R Smart, et al.
Pediatric Blood & Cancer|March 26, 2019
Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlatesAmber M Yates, Vijaya M Joshi, Banu Aygun, et al.
Transfusion|December 28, 2020
Safety and benefits of automated red cell depletion-exchange compared to standard exchange in patients with sickle cell disease undergoing chronic transfusionYonah Ziemba, Cindy Xu, Katayoun M Fomani, et al.
The New England Journal of Medicine|December 4, 2018
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaLéon Tshilolo, George Tomlinson, Thomas N Williams, et al.
Journal of Magnetic Resonance Imaging : JMRI|June 13, 2014
Comparing segmented ASL perfusion of vascular territories using manual versus semiautomated techniques in children with sickle cell anemiaKathleen J Helton, John O Glass, Wilburn E Reddick, et al.
Blood|August 31, 2011
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemiaRussell E Ware, Jenny M Despotovic, Nicole A Mortier, et al.
American Journal of Hematology|July 18, 2013
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trialOfelia Alvarez, Nancy A Yovetich, J Paul Scott, et al.
Pageof 8